Literature DB >> 17127214

Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human.

Shi-Shan Deng1, Tian-Yong Xing, Hong-Ying Zhou, Ruo-Hong Xiong, You-Guang Lu, Bin Wen, Shang-Qing Liu, Hui-Jun Yang.   

Abstract

Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF-MS), incorporated with online database searching, were performed to investigate differential proteins of breast cancer and adjacent normal breast tissues. Considering that serum albumin is abundantly presented in normal control samples, 15 differential spots detected in 11 out of 12 (91.7%) breast cancer samples were identified by online SIENA-2DPAGE database searching and MALDI-TOF/TOF-MS analysis. The results indicate that pathological changes of breast cancer are concerned with augmentation of substance metabolism, promotion of proteolytic activity, decline of activity of some inhibitors of enzymes, and so on. Some important proteins involved in the pathological process of breast cancer with changed expression may be useful biomarkers, such as alpha-1-antitrypsin, EF-1-beta, cathepsin D, TCTP, SMT3A, RPS12, and PSMA1, among which SMT3A, RPS12, and PSMA1 were first reported for breast cancer in this study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127214      PMCID: PMC5054074          DOI: 10.1016/S1672-0229(06)60029-6

Source DB:  PubMed          Journal:  Genomics Proteomics Bioinformatics        ISSN: 1672-0229            Impact factor:   7.691


Introduction

Breast cancer is a much commonly diagnosed cancer that is a leading cause of death for women (. The tumorigenesis and progression toward malignancy of breast cancer are an extremely complex event involved in multiple agents, including hormones, genetic mutations, and various physical, chemical, and organismic agents from outside environment 2., 3.. Although breast cancer has been studied extensively during the past several decades, the underlying molecular mechanism is currently not fully understood. Genes are the essential genetic materials to control cellular biological characteristics while proteins perform varied and vital cellular functions in movement, and all cellular behaviors in life can almost be interpreted in the protein level. In both category and abundance, the expressed proteins in breast cancer cells are different from those in normal breast cells. To elucidate the underlying molecular mechanism and search for new markers involved in clinical diagnosis, treatment, and prognosis, in recent years many efforts have been made to study the differentially expressed proteins in breast cancer cells compared with normal controls by proteomic methods 4., 5., 6.. The known genetic background and consistent cellular composition are the main characteristics of cell lines distinguished from tissues; therefore, breast cancer cell lines are the most common samples used to make proteomic analysis of human breast cancer in the mechanism of tumorigenesis, the effect and resistance of drugs, and prognosis 7., 8., 9.. However, the growth and progression of breast tumor cells not only depend on their malignant potential but also depend on agents presented in the tumor microenvironment. There are interactions among cells and between cells and agents in their surroundings. Proteins extracted from cell lines are only a part of the total proteins correlated to breast cancer. To make the best of obtaining all the information of proteins correlated to breast cancer, some other samples have been used for breast cancer proteomic analysis in recent several years, including tissue, serum, nipple aspirate fluid, interstitial cells, and so on 10., 11., 12., 13.. In this study, two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and matrix-assisted laser desorption/ionization tandem time-of-flight mass spectrometry (MALDI-TOF/TOF-MS), incorporated with online database searching, were performed to investigate differential proteins of breast cancer and adjacent normal breast tissues. The majority of pI values of proteins are within 5.0–8.0, therefore, the linear immobilized pH gradient (IPG) strips of pH 5.0–8.0 were used.

Results

More than 85% of the 2D gel images of all samples from both breast cancer and normal breast tissues were analyzed. As a result, about 1,000 spots from breast cancer tissue and 150 spots from normal breast tissue were detected (Figure 1). According to the image of sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE; Figure 2), we found that the protein content of the main strip (66.2 kDa) in normal control was two folds more than that in breast cancer sample. The majority of the proteins in normal control was identified as serum albumin (. The proportion of serum albumin to the total protein in normal breast tissue was reckoned to be approximately 80%. Furthermore, only about 400 spots were detected in breast cancer tissue when 50% loading content of samples was used in isoelectronic focusing (IEF). Therefore, proteins were thought to be up-regulated in breast cancer tissue when their abundance was four folds more than that in normal control. Proteins that increased less than four folds were thought to be possibly up-regulated. The other proteins with unchanged or decreased abundance were thought to be down-regulated in breast cancer tissue.
Fig. 1

The silver-staining 2D gels of proteins from normal breast tissue (A) and breast infiltrating ductal carcinoma tissue (B).

Fig. 2

The SDS-PAGE gel (coomassie brilliant blue R-250-staining). M: Protein marker; A: Normal breast tissue; Β: Breast infiltrating ductal carcinoma tissue; Β*: Breast infiltrating ductal carcinoma tissue with two-fold loading content more than that in A or Β.

Consequently, 15 differential spots were detected in 11 out of 12 (91.7%) breast cancer samples. These spots were then identified by searching in the online SIENA-2DPAGE database and MALDI-TOF/TOF-MS analysis. Among the 15 spots, 6 were up-regulated, 5 were down-regulated, and 4 (<4 folds) were possible to be up-regulated in the infiltrating ductal carcinoma samples (Table 1).
Table 1

Protein Annotations from Breast Cancer and Normal Breast Tissues Identified by 2-DE*

GroupSpot IDMWpIAccession No.Spots identified
Down-regulation
Pd167,5025.98P02768Serum albumin
Pd288,0297.54P99006Immunoglobulin heavy chain gama
Pd358,6144.91P01009Alpha-1-antitrypsin
Pd423,9895.12P02647ApolipoproteinA-I (apoA-I)
Pd525,7056.41P99007Immunoglobulin light chain

Probably Up-regulation
Pd673,5784.99P1102178 kDa Glucose-regulated protein (GRP78) (immunoglobin heavy chain binding protein) (BIP)
Pd716,0865.41P00441Superoxide dismutase (SOD)
Pd814,0005.05P02766Transthyretin (TBPA)
Pms121,072.57.63P37802Transgelin 2

Up-regulationPd929,5144.57P24534Elongation factor 1-beta (EF-1-beta)
Pd1028,2065.27P07339Cathepsin D
Pd1121,7884.87P13693Translationally controlled tumor protein (TCTP)
Pms211,7045.89P55854Small ubiquitin-related modifier 3 precursor (SMT3A) (SUM03)
Pms314,9056.81P63324Ribosomal protein S12 (RPS12)
Pms429,578.96.15P25786Proteasome subunit alpha type 1 (PSMA1)

Pd: Proteins identified by searching in the SIENA-2DPAGE database; Pms: Proteins identified by MALDI-TOF-TOF-MS; MW: molecular weight.

Discussion

Tumorigenesis of breast cancer is a much more complicated event correlated with multiple agents in vivo and in vitro 14., 15., 16.. Carcinomatous changes of cells are tightly concerned with agents in microenvironment 17., 18.. Changes of protein expressions in breast cancer tissues may play an important role in the tumorigenesis of breast cancer. Proteins from tissues are better to show cellular biological characteristics than those from cell lines (. The structure and function of cancer cells are different from those of normal cells, thus proteins expressed by cancer cells are different from those by normal cells. Proteins from tissues comprise not only intracellular proteins but also proteins secreted to the outside of cells, and extracellular proteins may be secreted from either non-breast cells or non-breast cancer cells. Furthermore, in this study the normal breast tissues contained rich connective tissues but few breast ductal and lobular cells that presented non-active function in the non-lactation period of volunteers with the age between 32–60 years (Figure 3). Therefore, many proteins with low abundance from normal breast cells were not detected. The results in both single SDS-PAGE gel (Figure 2) and 2D-PAGE gel (Figure 1) showed that proteins expressed in cancer tissue were extremely different from those in normal tissue. Since serum albumin is the majority of the total protein content in normal tissue sample, the loading content of each protein in normal control was quite different from that in cancer tissue sample. Consequently, many proteins were not detected by 2D-PAGE, and differential protein spots in 2D-PAGE gels were not completely differential proteins in expression but maybe the same abundant protein that was possibly different in expression. On the basis of serum albumin being abundantly presented in normal tissue, proteins were thought to be up-regulated in breast cancer tissue when their abundance was four folds more than that in normal control. Proteins with unchanged or decreased abundance were thought to be down-regulated in breast cancer tissue. Proteins that increased less than four folds in 2D-PAGE were thought to be possibly up-regulated because the difference may be not resulted from breast cancer.
Fig. 3

The hematoxylin and eosin (H&E)-staining images (100 folds) of normal breast tissue (A) and breast infiltrating ductal carcinoma tissue (B).

In this study, five proteins were down-regulated in breast cancer tissue, including serum albumin, immunoglobulin heavy chain gama, immunoglobulin light chain, apolipoproteinA-I (apoA-I), and alpha-1-antitrypsin. Serum albumin, whose main function is the regulation of the colloidal osmotic pressure of blood, is the main protein of plasma. Both immunoglobulin heavy chain gama and immunoglobulin light chain are components of seroglobulin. ApoA-I, which is the major protein of plasma high density lipoprotein (HDL), participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase. The above four proteins are the exactly components of plasma proteins, and down-regulation of those proteins suggests that blood supply for cancer tissue is less than that for normal breast tissue. The concentrations of key proteins in diverse regulatory pathways are controlled by post-translational ubiquitination and degradation by the 26S proteasome. Therefore, alterations in this proteolytic system are associated with pathologies of breast cancer 20., 21., 22.. The up-regulation of small ubiquitin-related modifier 3 precursor (SMT3A) and proteasome subunit alpha type 1 (PSMA1) indicate that the action of ubiquitin-proteasome system in breast cancer is strengthened. In addition, cathepsin D, which possesses acid proteases active in intracellular protein breakdown, is currently thought to correlate to the pathogenesis of breast cancer 23., 24., 25.. The over-expressin of cathepsin D in breast cancer may be involved in tissue infiltration. Proteolytic enzymes could be very important in the spread of cancer, but the role of the body’s natural inhibitors of these enzymes in this process is rarely reported. Alpha-1-antitrypsin is an inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. It was reported that the activity of alpha-1-antitrypsin was significantly lower in patients with breast cancer before surgery than that in the controls, while after six months an increase in alpha-1-antitrypsin activity was observed (. Goodarzi and Turner ( reported that patients were unresponsive to treatment when high amounts of alpha-1-antitrypsin were extracted, and the carbohydrate structure of alpha-1-antitrypsin was also altered in cancer. Therefore, the down-regulation of alpha-1-antitrypsin suggests that it might play an important role in pathological progression in breast cancer. Malignant cells proliferate actively and substance metabolism is concomitantly enhanced. The up-regulation of elongation factor 1-beta (EF-1-beta) and ribosomal protein S12 (RPS12) may be related to the promotion of protein synthesis. The elongation step of protein synthesis involves binding of aminoacyl-tRNA to the ribosomal A site, formation of a peptide bond, and translocation of the newly formed peptidyl-tRNA to the Ρ site. The nucleotide exchange factor EF-1-beta plays a major role in the regulation of this process by regenerating a GTP-bound EF-1-alpha that is necessary for each elongation cycle (. However, the function of RPS12 is currently unknown. Cheng et al. 28., 29. found that the gene expression of RPS12 altered in the adjacent histopathologically “normal” cervical squamous epithelial tissue from cervical cancer patients, and thought that RPS12 may be potentially useful as an early pre-transformation diagnostic marker for human cervical cancer. Translationally controlled tumor protein (TCTP) is involved in calcium binding and microtubule stabilization, and may be concerned with cell migration. Some antihistaminic compounds and other pharmacological compounds with a related structure could kill tumor cells and significantly decrease the gene level of TCTP (. Vercoutter-Edouart et al. ( also found that the up-regulation of TCTP occurred in MCF-7 human breast cancer cells induced by fibroblast growth factor-2 (FGF-2) stimulation. The up-regulation of TCTP in breast cancer indicates that TCTP might be a useful biomarker for breast cancer. In 2D-PAGE gels, there were many low abundant proteins, the majority of which were not detected when the loading content of samples in IEF was decreased at 50%. Besides, serum albumin is abundantly presented in normal control sample, which may impact on experimental results. Therefore, only four proteins, namely 78 kDa glucose-regulated protein (GRP78), superoxide dismutase (SOD), transthyretin (TBPA), and transgelin 2, were identified and analyzed. These four proteins increased in breast cancer but were less than four folds, thus they were possible to be up-regulated in breast cancer. The alteration of transthyretin concentrations might compensate for changes in free thyroxine and thus the change of transthyretin may be involved in the substance metabolism in breast cancer (. Over-expression of the GRP78 gene in malignant but not benign human breast lesions ( with the changes of SOD and GRP78 might be correlated with stress reaction in cancer. Transgelin 2 was identified by MALDI-TOF/TOF-MS but its function has not been understood. Shi et al. ( found that transgelin 2 mRNA was over-expressed in hepatocellular carcinoma (HCC) patients and thought that transgelin 2 mRNA may be a diagnostic marker for HCC. The report related to the role of transgelin 2 in breast cancer has not been seen, and its function needs to be further verified.

Conclusion

On the whole, breast cancer has a very complicated pathological process. In this study, we verified that pathological changes of breast cancer are concerned with augmentation of substance metabolism, promotion of proteolytic activity, decline of activity of some inhibitors of enzymes, and so on. Some important proteins with changes in expression are involved in the pathological process of breast cancer and may be useful biomarkers correlated to diagnosis, treatment effects, and prognosis for patients with breast cancer, such as alpha-1-antitrypsin, EF-1-beta, cathepsin D, TCTP, SMT3A, RPS12, and PSMA1. Among these proteins, SMT3A, RPS12, and PSMA1 were first reported for breast cancer in this study.

Materials and Methods

Tissue specimens

The fresh breast cancer tissues and adjacent normal breast tissues were obtained at excision of surgical operation from 12 volunteers between 32–60 years old with breast cancer at different clinical stages [T1N1M0 (n=1), T2N1M0 (n=4), T2N2M0 (n=1), T2N3M0 (n=2), T3N2M0 (n=3), and T3N3M1 (n=1)] at the Affiliated Hospital of North Sichuan Medial College, Nanchong, China. The tissues were frozen in −150°C super low temperature icebox (Revco, Asheville, USA) as soon as mastectomy was done. All samples were examined pathologically to obtain representative, viable, and non-necrotic tissues. The breast cancer was pathologically identified as infiltrating ductal carcinoma (Figure 3).

Protein sample preparation

Tissue protein extraction was accomplished by the ReadyPre™ Protein Extraction Kit (Total Protein) provided by Bio-Rad (Hercules, USA). The protein samples were then stored in aliquots of 200 μL at −80°C. To measure the concentration of the total protein, the Bio-Rad RC DC Protein Assay was used. Since the protein samples contained substances like salts, nucleic acids, and lipids, all of which are known to interfere with IEF, the ReadyPre™ 2-D Cleanup Kit (Bio-Rad) was used to wash them away and to concentrate proteins in samples at the same time. Before IEF, the concentration of protein samples was measured by using the Bio-Rad RC DC Protein Assay once more.

2D-PAGE and gel staining

Before 2D-PAGE, SDS-PAGE was firstly performed to preliminarily analyze the differences of proteins expressed in breast cancer and normal tissues (Figure 2), respectively. The loading content of protein samples was 35 μg. The first-dimension IEF was performed with precast IPG strips (pH 5.0–8.0, linear pH IPG, 178×3.3×0.5 mm; Bio-Rad) using the focusing tray (Bio-Rad). The loading volume of protein samples was 320 μL (The loading content of protein samples was 500 μg stained with silver nitrate and 2 mg stained with coomassie brilliant blue R-250 in each gel). IEF was carried out at 20°C with 50 μA/strip under the following conditions: Rehydration, 50 V, 12 h, passive; S1., 250 V, 25 min, slow; S2, 1,000 V, 2 h, rapid; S3, 8,000 V, 5 h, linear; S4, 8,000 V, 60,000 Vh, rapid; S5, 500 V, arbitrary. After IEF, it was necessary to equilibrate the IPG strips in a buffer containing SDS. The strips were first equilibrated in a buffer containing 6 M urea, 0.375 M Tris-HCl (pH 8.8), 2% SDS, 20% glycerol, and 2% (w/v) dithiothreitol for 15 min, and then in a buffer containing 6 M urea, 0.375 M Tris-HCl (pH 8.8), 2% SDS, 20% glycerol, and 2.5% (w/v) iodoacetamide for another 15 min. The equilibrated strips were placed on top of the prepared 12% SDS polyacrylamide gels and sealed in place with 0.5% low-melt agarose (Sigma, St. Louis, USA). The SDS-PAGE was performed at a current of 16 mA/gel for 30 min, then at another current of 24 mA/gel at 4°C for about 5 h using PROTEANII® Xi Cell (Bio-Rad). After 2D-PAGE, the gels were stained with silver nitrate for analysis or with coomassie brilliant blue R-250 for preparative purposes.

Scanning and image analysis

The stained gels were scanned by UMAXpowerlook 1120 (UMAX, Taiwan, China) and analyzed by using the PDQuest 7.0 software (Bio-Rad), and the results in differential protein spots in gels from breast cancer and adjacent normal tissues were determined.

Identification of protein spots in gels

The 2D-PAGE images were compared with the online counterparts of the SIENA-2DPAGE database (http://www.bio-mol.unisi.it/cgi-bin/map1), and then the correlative information of differential protein spots was acquired by clicking on a spot located in the same point in the corresponding 2D-PAGE maps of the SIENA-2DPAGE database. Some differential spots whose correlative information was not obtained from the SIENA-2DPAGE database was identified by MALDI-TOF/TOF-MS (.

Authors’ contributions

SSD carried out the protein extraction, 2-DE separation and identification, participated in the PDQuest analysis of 2-DE gel images, and drafted the manuscript. TYX carried out the collection of tissue samples. HYZ participated in the design of the study. RHX participated in the protein extraction and 2-DE separation. YGL participated in the PDQuest analysis of 2-DE gel images. BW carried out the pathological identification of tissue samples. SQL participated in the 2-DE separation. HJY conceived of the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors have declared that no competing interests exist.
  35 in total

1.  Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses.

Authors:  Karim Chahed; Maria Kabbage; Laurence Ehret-Sabatier; Christelle Lemaitre-Guillier; Sami Remadi; Johan Hoebeke; Lotfi Chouchane
Journal:  Int J Oncol       Date:  2005-11       Impact factor: 5.650

2.  Proteomics of bovine myelin sheath: characterization of a truncated form of P0 by MALDI-TOF/TOF mass spectrometry.

Authors:  Antonio Qualtieri; Elena Urso; Maria Le Pera; Massimo Scornaienchi; Aldo Quattrone; Leonardo Di Donna; Anna Napoli; Giovanni Sindona
Journal:  J Am Soc Mass Spectrom       Date:  2006-01-10       Impact factor: 3.109

3.  Transthyretin--an explanation of "anomalous" serum thyroid hormone values in severe illness?

Authors:  J Ramaker; W G Wood
Journal:  J Clin Chem Clin Biochem       Date:  1990-03

Review 4.  Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors.

Authors:  Håkan Axelson; Erik Fredlund; Marie Ovenberger; Göran Landberg; Sven Påhlman
Journal:  Semin Cell Dev Biol       Date:  2005-04-26       Impact factor: 7.727

5.  Comparative proteome analysis of breast cancer and normal breast.

Authors:  Yuanming Luo; Jindan Zhang; Yanxin Liu; Allan Christian Shaw; Xiaorong Wang; Shuzhen Wu; Xuan Zeng; Jie Chen; Youhe Gao; Dexian Zheng
Journal:  Mol Biotechnol       Date:  2005-03       Impact factor: 2.695

6.  Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions.

Authors:  P M Fernandez; S O Tabbara; L K Jacobs; F C Manning; T N Tsangaris; A M Schwartz; K A Kennedy; S R Patierno
Journal:  Breast Cancer Res Treat       Date:  2000-01       Impact factor: 4.872

7.  Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r.

Authors:  Martina Huber; Inke Bahr; Jörn R Krätzschmar; Andreas Becker; Eva-Christina Müller; Peter Donner; Hans-Dieter Pohlenz; Martin R Schneider; Anette Sommer
Journal:  Mol Cell Proteomics       Date:  2003-10-13       Impact factor: 5.911

8.  Differential proteome analysis of replicative senescence in rat embryo fibroblasts.

Authors:  Silvia Benvenuti; Rainer Cramer; Christopher C Quinn; Jim Bruce; Marketa Zvelebil; Steven Corless; Jacquelyn Bond; Alice Yang; Susan Hockfield; Alma L Burlingame; Michael D Waterfield; Parmjit S Jat
Journal:  Mol Cell Proteomics       Date:  2002-04       Impact factor: 5.911

9.  Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix.

Authors:  Q Cheng; W M Lau; S H Chew; T H Ho; S K Tay; K M Hui
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

10.  Identification and analysis of tumour-associated antigens in hepatocellular carcinoma.

Authors:  Y-Y Shi; H-C Wang; Y-H Yin; W-S Sun; Y Li; C-Q Zhang; Y Wang; S Wang; W-F Chen
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

View more
  20 in total

1.  Expression and clinical role of TCTP in epithelial ovarian cancer.

Authors:  Chen Chen; Yan Deng; Minhui Hua; Qinghua Xi; Rong Liu; Shuyun Yang; Jian Liu; Jianxin Zhong; Meilan Tang; Shumin Lu; Zhimei Zhang; Xiao Min; Chunhui Tang; Yingying Wang
Journal:  J Mol Histol       Date:  2015-01-07       Impact factor: 2.611

2.  Distinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypes.

Authors:  Rajasree Menon; Hogune Im; Emma Yue Zhang; Shiaw-Lin Wu; Rui Chen; Michael Snyder; William S Hancock; Gilbert S Omenn
Journal:  J Proteome Res       Date:  2013-11-07       Impact factor: 4.466

3.  Comparative proteomic analysis of fibrosarcoma and skin fibroblast cell lines.

Authors:  Ogunc Meral; Hamdi Uysal
Journal:  Tumour Biol       Date:  2014-10-01

4.  Comparative modelling unravels the structural features of eukaryotic TCTP implicated in its multifunctional properties: an in silico approach.

Authors:  Rakesh Kumar; Shweta Saran
Journal:  J Mol Model       Date:  2021-01-07       Impact factor: 1.810

5.  Reciprocal repression between P53 and TCTP.

Authors:  Robert Amson; Salvatore Pece; Alexandra Lespagnol; Rajesh Vyas; Giovanni Mazzarol; Daniela Tosoni; Ivan Colaluca; Giuseppe Viale; Sylvie Rodrigues-Ferreira; Jessika Wynendaele; Olivier Chaloin; Johan Hoebeke; Jean-Christophe Marine; Pier Paolo Di Fiore; Adam Telerman
Journal:  Nat Med       Date:  2011-12-11       Impact factor: 53.440

6.  Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.

Authors:  Virginie Baylot; Maria Katsogiannou; Claudia Andrieu; David Taieb; Julie Acunzo; Sophie Giusiano; Ladan Fazli; Martin Gleave; Carmen Garrido; Palma Rocchi
Journal:  Mol Ther       Date:  2012-08-14       Impact factor: 11.454

7.  TCTP overexpression is associated with the development and progression of glioma.

Authors:  Xia Miao; Yong-Bin Chen; Sheng-Long Xu; Tao Zhao; Jun-Ye Liu; Yu-Rong Li; Jin Wang; Jie Zhang; Guo-Zhen Guo
Journal:  Tumour Biol       Date:  2013-06-09

8.  Breast cancer and protein biomarkers.

Authors:  Lay-Harn Gam
Journal:  World J Exp Med       Date:  2012-10-20

9.  Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.

Authors:  Pavel Gromov; Irina Gromova; Jakob Bunkenborg; Teresa Cabezon; José M A Moreira; Vera Timmermans-Wielenga; Peter Roepstorff; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2009-11-23       Impact factor: 6.603

10.  dbDEPC: a database of differentially expressed proteins in human cancers.

Authors:  Hong Li; Ying He; Guohui Ding; Chuan Wang; Lu Xie; Yixue Li
Journal:  Nucleic Acids Res       Date:  2009-11-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.